MEN1703 is a first-in-class orally available dual PIM and FLT3 kinase inhibitor discovered by Selvita (now Ryvu Therapeutics) and acquired by the Menarini Group at the beginning of 2017.
The molecule has a unique activity profile for its ability of inhibiting both PIM kinase, important for cell cycle regulation, cell survival and tumorigenesis, and FLT3, a kinase involved in the onset and progression of acute myeloid leukemia (AML).
None of the molecules currently in clinical development has this dual activity.
The Phase I/II clinical trial DIAMOND in patients with relapsed /refractory AML is ongoing.
VISIT OUR CLINICAL TRIALS DATABASE
Preliminary preclinical evidence suggests activity not only in hematological tumors but also in solid tumors and additional studies to select new indications are ongoing.